Emyria Engages Calvert Labs for Preclinical CBD studies
Filed with ASX · · 3 pages · English
● Emyria has signed a Master Services Agreement (MSA) with leading North American preclinical contract research organisation (CRO), Calvert Labs, an Altasciences Company in support of Emyria’s TGA and FDA registration programs ● Calvert Labs, an Altasciences Company, has a proven track record of performing FDA-approved studies across a broad range of therapeutic indications and specialises in the
Earlier from Emyria
- Emyria Appoints Expert Neuropharmacologist for MDMA Program
- Emyria Executes Pure CBD Agreement with AltaSciences
- Emyria to Develop Novel Psychedelics Pipeline with UWA
- Emyria Advances EMD-004 Program Towards Registration
- Emyria Data Validated, Care Model Reduces Opioids
Later from Emyria
- MDMA-analogues Show Promise for Parkinsons Disease
- Emyria Expands Psychiatry Advisory for Psychedelics and MDMA
- Novel MDMA Analogue Screening Program Advanced
- Emyria selected to join Palantirs Foundry Builders Program
- MDMA Analogue Development Milestone
Follow Emyria into a list and get an email when it puts out news.
Follow Emyria